NASDAQ:TCDA - Tricida Stock Price, News, & Analysis

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) issued its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.60) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.00) by $0.40. View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Tricida.

3 Wall Street analysts have issued 12 month price objectives for Tricida's stock. Their forecasts range from $32.00 to $50.00. On average, they expect Tricida's stock price to reach $38.6667 in the next twelve months. This suggests a possible upside of 70.0% from the stock's current price. View Analyst Price Targets for Tricida.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tricida.

News coverage about TCDA stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tricida earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Some companies that are related to Tricida include Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Intercept Pharmaceuticals (ICPT), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), Reata Pharmaceuticals (RETA), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA) and Mirati Therapeutics (MRTX).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida's lock-up period expired on Tuesday, December 25th. Tricida had issued 11,700,000 shares in its public offering on June 28th. The total size of the offering was $222,300,000 based on an initial share price of $19.00. Since the end of Tricida's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Tricida's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (4.16%), BlackRock Inc. (3.80%), Massachusetts Financial Services Co. MA (0.49%), Geode Capital Management LLC (0.45%), Northern Trust Corp (0.38%) and Artal Group S.A. (0.30%). Company insiders that own Tricida stock include Beek Jeroen B Van, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Sandra I Coufal and Steffen Pietzke. View Institutional Ownership Trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, MetLife Investment Advisors LLC, United Services Automobile Association and Citigroup Inc.. Company insiders that have sold Tricida company stock in the last year include Claire Lockey, Dawn Parsell Otto, Klaus R Dr Veitinger and Sandra I Coufal. View Insider Buying and Selling for Tricida.

TCDA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Opaleye Management Inc., Artal Group S.A., Eversept Partners LP, Bank of New York Mellon Corp, Geode Capital Management LLC, Northern Trust Corp and Virtus ETF Advisers LLC. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $22.75.

Tricida has a market capitalization of $957.93 million. Tricida employs 61 workers across the globe.

The official website for Tricida is http://www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]